When a Blood Test Actually Settles This
A test earns its place when a plausible result would change what happens next. That is the whole of the principle, and applied honestly to low desire it produces an uncomfortable split: a small number of tests are genuinely decisive, a larger number are worth having for reasons that have little to do with desire, and a third group is sold heavily and settles nothing at all.
The low libido hub lists what is measurable. This page is about which of it is worth measuring, in whom, and what you should expect a result to do.
Where testing genuinely changes the answer
An abrupt change in a man, with other features. This is the strongest case on the page, and it is the reason a blanket "you do not need a test" would be wrong. Desire that fell over months rather than years, alongside loss of morning erections, shrinking testicles, breast tissue, headaches or any change in vision, is a picture that needs a hormonal workup rather than reassurance. Where testosterone is low and the pituitary signal driving it is not raised to compensate, the problem sits above the testicles rather than in them — which is the sequence that turns up a pituitary cause.
Prolactin, for the same reason. A prolactin-secreting pituitary tumor can present as low desire before it presents as anything else, in both sexes. It is a benign tumor, it is found with a blood test, and it is usually treated with tablets rather than surgery. It is the clearest example of testing changing an answer completely, and it is the main argument against handling low desire by questionnaire alone.
Thyroid function. Both directions flatten energy, mood and desire. Common, easily measured, and frequently absent from a routine panel.
Testosterone in a man, done properly. Levels move across the day and between draws, so a single sample is close to uninterpretable. It is measured in the morning and confirmed on a second morning sample before anything is concluded, and it is read alongside sex hormone binding globulin, because a total figure can look adequate while the fraction available to tissue is not. Above all it is read alongside symptoms — a number without a history is not a diagnosis. Low testosterone covers this in full.
Iron status in women who bleed heavily. Fatigue and flattened desire arrive well before anemia is visible on a standard blood count. It is cheap, it is routinely skipped, and it is one of the more satisfying things to find.
Glucose and lipids. These rarely explain the desire complaint by themselves. They are on the list because vascular health underpins arousal in both sexes and because the result changes the medical plan whatever it says about sex — which is a good enough reason on its own.
Where testing usually does not change the answer
A testosterone level in a woman with low desire. This is the most heavily marketed test in the category and the one with the least decision value. There is no established level at which a woman is deficient, no validated threshold for diagnosis, and a level does not predict who will respond to treatment. Professional-society guidance is that it is not used to diagnose low desire in women, and where testosterone is prescribed it is on the clinical picture, with levels used to check that treatment has not overshot rather than to justify starting. That distinction matters, because a great deal of direct-to-consumer marketing inverts it. See testosterone in women.
A single hormone panel to diagnose perimenopause. Hormones swing widely across a perimenopausal cycle, so one draw can read as anything. The diagnosis is clinical — symptoms and cycle history — and testing is for other purposes. See when in your cycle to test hormones and menopause.
Salivary hormone panels, urinary "neurotransmitter" testing and the broader wellness-panel genre. These are sold hard into exactly this complaint. They are not validated for it, and a result that cannot be acted on is not information.
A panel ordered before the history is taken. The most common error is not the wrong test; it is the right test ordered too early. In this complaint the medication list, the sleep history, the alcohol history and the date of onset settle more cases than the panel does, and they also determine what the panel means when it comes back.
The two traps a result sets
The normal result read as a dead end. People arrive deflated by a clean panel, as though nothing was found. Something was found: several causes were excluded, and the question has moved to sleep, medications, mood, alcohol, pain and context — which is where the answer was always most likely to be, and where a good deal of it is modifiable. When the cause is not in the blood is the page for that.
The incidental abnormality treated as the cause. Run enough tests and something will sit slightly outside a reference range. In a man with an intact history, a marginal hormone result is not automatically the explanation for a symptom with four other plausible causes — and treating it is how someone ends up on monitored therapy for years while the antidepressant, the untreated sleep-disordered breathing or the low mood that actually caused this continues unexamined. A borderline number is a reason to look harder, not a reason to prescribe.
We will not treat a normal result in order to sell something. That commitment is only meaningful if it also means we will sometimes tell you the panel did not find your answer.
Frequently asked questions
In men: testosterone on a morning sample and confirmed, with sex hormone binding globulin and prolactin, plus thyroid function. In women: thyroid function, iron status where bleeding is heavy, and prolactin where the change was abrupt. In both, glucose and lipids for reasons that go well beyond this complaint.
Usually not to answer this question. There is no validated threshold for deficiency in women and a level does not predict who responds to treatment. Where testosterone is used it is decided on the clinical picture, and levels are used to confirm treatment has not overshot.
Because levels vary across the day and between draws. A single result is not a diagnosis. It is taken in the morning and confirmed on a second morning sample before anything is concluded.
That narrows things usefully. It moves the question to medications, sleep, alcohol, mood and context — none of which a panel would have shown, and several of which are more modifiable than a hormone.
Occasionally, and that is why an abrupt change gets a proper workup. A prolactin-secreting pituitary tumor can present this way, as can thyroid disease and untreated diabetes. This is uncommon, and it is findable.
You can, and the limitation is not the blood draw — it is that a result without a history is hard to act on, and easy to act on wrongly. See lab testing for what we run and how it is read.
Where this fits in your plan
Start with the part that decides what the panel means: the full medication list, an honest account of sleep and alcohol, when the change began, and whether it is the same alone as it is with a partner. Then the baseline panel, read against all of it.
Before any test, ours included, the question worth asking is what you would do differently depending on the result. If the answer is nothing, the test is not the next step. If the answer is something specific, it is.
We measure first. Then we act.
References
- American Urological Association. Testosterone Deficiency Guideline — diagnosis, morning sampling and confirmatory testing.
- Endocrine Society. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
- Endocrine Society. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline.
- Global Consensus Position Statement on the Use of Testosterone Therapy for Women.
- American College of Obstetricians and Gynecologists. Female Sexual Dysfunction — ACOG Practice Bulletin.
- The Menopause Society (formerly the North American Menopause Society). Hormone Therapy Position Statement — diagnosis of the menopausal transition.
- Back toLow Libido
- Desire is not arousalDesire, arousal and function are separate systems with separate causes. Which one changed decides what is worth treating — and what will not.Read
- Medications that lower libidoAntidepressants, finasteride, some blood pressure drugs, hormonal contraception and opioids all reduce desire. How to tell, and what to ask your prescriber.Read
- Responsive vs spontaneous desireMany people never feel desire out of nowhere — it arrives after arousal. That is a pattern, not a deficiency, and it changes what is worth treating.Read
- When the cause is not in the bloodSleep debt, chronic stress, a changed body, past pain and relationship context all suppress desire and none of them show on a blood test. Taken seriously.Read
- Low testosteroneWhat low testosterone actually looks like after 40, what else produces the same picture, and how it is properly measured.Read
- Lab testingComprehensive blood, hormone, gut, methylation and glucose testing — the baseline every plan is built on.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.